Safety of extended treatment with anakinra in patients with rheumatoid arthritis - Test2 - elhamkhani - TriplyDB

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

http://www.wikidata.org/entity/Q24675209

about

Adverse effects of biologics: a network meta-analysis and Cochrane overview Anakinra for rheumatoid arthritis The IL-1 cytokine family and its role in inflammation and fibrosis in the lung Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies Targeting interleukin-1 in heart disease Evasion of inflammasome activation by microbial pathogens Interleukin-6 mediates epithelial-stromal interactions and promotes gastric tumorigenesis Oxidized Low-Density Lipoprotein Immune Complex Priming of the Nlrp3 Inflammasome Involves TLR and FcγR Cooperation and Is Dependent on CARD9 Inhibition of interleukin-1β decreases aneurysm formation and progression in a novel model of thoracic aortic aneurysms.Genetic and pharmacologic disruption of interleukin-1β signaling inhibits experimental aortic aneurysm formation.Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review.Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project.Translational pharmacokinetics: challenges of an emerging approach to drug development in stroke.Biologics and heart failure in rheumatoid arthritis: are we any wiser?Interleukin-1 receptor signaling is required to overcome the effects of pertussis toxin and for efficient infection- or vaccination-induced immunity against Bordetella pertussis.Leukocyte activity in patients with ST-segment elevation acute myocardial infarction treated with anakinra Blocking interleukin-1 in rheumatic diseases Inflammasomes and their activation.IL-1β suppresses innate IL-25 and IL-33 production and maintains helminth chronicity.Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension.Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports Memory deficits induced by inflammation are regulated by α5-subunit-containing GABAA receptors.Treating rheumatic patients with a malignancy.The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.Serious infections with antirheumatic therapy: are biologicals worse?Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions.The acute pulmonary inflammatory response to the graded severity of smoke inhalation injury Conformational Sampling and Binding Site Assessment of Suppression of Tumorigenicity 2 Ectodomain Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Novel therapies for rheumatoid arthritis.Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders.Mutual amplification of HNF4α and IL-1R1 composes an inflammatory circuit in Helicobacter pylori associated gastric carcinogenesis Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.Mycobacterial disease in patients with rheumatic disease.Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature.

P2860

Q24234197-729A1725-4AB1-4B1C-BA2D-E3B2FEEB4714 Q24241707-EBC9ED3C-7D9A-4C3E-89D3-D498B9EF52B6 Q26752849-76F6A4EB-3743-46D8-A6C6-D388661FBAAE Q26799747-8BB68161-6097-40EB-8545-4711965F0AD7 Q27009347-8F999C1E-E314-4C5F-9917-BD377007D3DD Q28082757-FF4C7838-7A3C-44C4-A1D3-07F037AFE5A4 Q28486177-DCA3589F-A42E-4117-BC67-2D8A33D1586C Q30274903-CA5E6135-998B-4761-9286-8B032C6253BD Q30355344-92D43BDE-13AF-4169-9F33-EB482D26A507 Q30414961-DF270571-0C2E-444C-8471-34DDBA24EDBE Q31039549-9BACDF11-A958-42D1-BDA6-9ADFF42EC864 Q33315300-55A37375-03EC-4268-844D-876D6808E737 Q33346685-CADDBF59-B50A-4729-8733-54364F3F912D Q33573112-7F5756BD-5441-4283-9064-CBD525FA250C Q33882182-477D904F-B30B-40CD-B6F1-AA77A32E383D Q33898103-2D5EC125-C7EA-49EF-947D-4B02FA5ACD25 Q34484529-A2B502D4-0440-4B2E-BDFD-E31E35FE261F Q34777497-BC52E2C1-6D82-4423-ADFF-D25578AC6303 Q34822708-8AA46FE5-ABB9-49EF-8459-A9052156AC2F Q34905606-31E2D34E-5289-4107-9A27-03BD78D540BF Q34916928-8C9430C4-0784-4945-A155-1920944BCB8D Q35122583-05D9999C-6991-45EC-8945-6D58B2C5C05D Q35132715-70D983D6-661D-42A9-B90B-93F7C27394AA Q35225125-04E23C94-108D-44FF-9E51-A56FDEA2D014 Q35343518-C48A33BD-BA9A-4782-83AD-08D81CF1D495 Q35557863-B6829AC9-3831-46B1-92B0-D3C9CDBB1AE0 Q35617753-A5DDBC0A-B94F-4450-8AAC-5FD885E9E03D Q35638252-23574EAD-8E82-40CB-A764-11107CC0A78A Q35638259-5E51AE00-3EBA-4481-BEFF-C1E561026079 Q35683994-82BCE391-1B91-4549-B01C-16E66236ABF6 Q35791095-60D0CA6B-CF3F-48B4-AA95-714C1CF71182 Q35886682-33618D6D-3EEB-4DD4-82FE-3EEFC7FD50A6 Q36171750-23B200E9-51B2-49A5-A0EE-E3E5285A694A Q36623081-DA6DB05A-10C5-4ECC-A5B3-7F48213CD642 Q36816872-DF976D0B-9909-4DF7-A8C0-9E93C3CD26FC Q36859216-C0A17DE5-748A-45CB-BE5E-2FD81D294E89 Q36998254-48E56CD1-3B17-4165-991C-4BB215C32B2F Q37290665-C43A5321-78CA-4229-825C-8BFB99FAC0D5 Q37335860-DF5814AA-DAFE-47AB-BBD3-8D4F6BA50359 Q37358271-660A0DE9-C8FC-436B-AC8D-584901C94544

P2860

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

http://www.wikidata.org/entity/Q24675209

description

2006 nî lūn-bûn

@nan

2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

@ast

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

@en

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

@nl

type

label

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

@ast

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

@en

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

@nl

prefLabel

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

@ast

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

@en

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

@nl

P1433

Q24675209-09EDB8F0-8A4E-4DEE-93BE-AC0462ACF7F4

P1476

Q24675209-EF4BC4D7-EDD9-4E29-9044-F8014C5689B2

P2093

Q24675209-021599DF-6E8B-4DE1-A160-8E5D74EBC969

Q24675209-28BA1B5E-5089-4731-B970-9CCDC1A1FC2D

Q24675209-4EE5E5B6-DCA3-4E6A-B130-8562F35E1061

Q24675209-5D661459-6D30-4C95-8500-D327CCA45FE3

Q24675209-67ECF2D8-FE51-49FB-82CD-2FCF35ABA323

Q24675209-7DFFEB29-050E-4C32-B727-21977C557796

Q24675209-8987E509-FCD0-4E24-A22F-F6E46FD69FDC

Q24675209-D9D74594-7EA0-4AF2-B9D4-47C3E566CF39

Q24675209-E5032EB4-505E-4F8F-A4A5-6CFD38432E5F

Q24675209-F81C5E2D-3C60-4FE0-95EB-E46A8F8359C5

P2860

Q24675209-0B77DDD8-5007-4F12-8847-4C2FDEA840F9

Q24675209-0FB4C332-A9FA-4E8B-B3B3-733E23686589

Q24675209-1661770C-265D-4B0F-835C-F70C5A614E36

Q24675209-225F9F0A-BF51-41B2-A2D8-57B147A3FEDF

Q24675209-234E345F-FE82-4DD3-99E9-2B542C05CE0F

Q24675209-2A36C004-09BC-463F-8444-976FD6F3900C

Q24675209-38237284-28E0-4CC2-9726-3BD95C21DE4C

Q24675209-4759F518-1D6C-49BA-BCD7-C0838BDB8709

Q24675209-4B5E05CC-8548-4D7B-B35D-FC8E8AC93A02

Q24675209-54EE21EE-D43D-42A7-98A6-FBE75AA6C2D9

P304

Q24675209-EC8A2DCB-9E49-4D42-99D0-97491DDFBCE7

P31

Q24675209-BE21A17A-0AAA-4612-84F6-63EBD2611586

P3181

Q24675209-B2899C70-3E21-404F-85EA-9845496905E6

P356

Q24675209-4CF470D3-F7A7-48A3-9B6E-BA0EAEE8C527

P407

Q24675209-97A4AF4B-90D9-4FED-B894-7748E1215817

P433

Q24675209-5CF98D2F-673F-4B4C-840E-A5117851DD03

P478

Q24675209-58A38A37-9011-41F4-B51B-732FB877683E

P577

Q24675209-18A57CBD-A31C-414A-88B5-A4610D1E8E14

P5875

Q24675209-6ACE52B1-5A44-43A5-80F1-5917F38B3D82

P698

Q24675209-CC3CFC51-7775-43A4-A795-AD159C66A4FD

P932

Q24675209-0D1DE0B2-A522-4A63-BFB5-CF471DF6D4FD

P3181

P356

ARD.2005.048371

P1433

Annals of the Rheumatic Diseases

P1476

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

@en

P2093

B Appleton

http://www.w3.org/2001/XMLSchema#string

D Bell

http://www.w3.org/2001/XMLSchema#string

D Modafferi

http://www.w3.org/2001/XMLSchema#string

G-R Burmester

http://www.w3.org/2001/XMLSchema#string

J Schechtman

http://www.w3.org/2001/XMLSchema#string

J Tesser

http://www.w3.org/2001/XMLSchema#string

L Zhou

http://www.w3.org/2001/XMLSchema#string

M H Schiff

http://www.w3.org/2001/XMLSchema#string

R Bennett

http://www.w3.org/2001/XMLSchema#string

R M Fleischmann

http://www.w3.org/2001/XMLSchema#string

P2860

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Cancer morbidity in rheumatoid arthritis.

Lymphoproliferative malignancy in rheumatoid arthritis: a study of 20 cases.

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.

P304

1006-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2234833

http://www.w3.org/2001/XMLSchema#string

P356

10.1136/ARD.2005.048371

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7374673

http://www.w3.org/2001/XMLSchema#string

P698

16396977

http://www.w3.org/2001/XMLSchema#string

P932

1798263

http://www.w3.org/2001/XMLSchema#string